By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment house William Blair on Monday initiated coverage of Pacific Biosciences and Complete Genomics.

Analyst Amanda Murphy gave PacBio a "Market Perform" rating and an "Aggressive Growth" profile, and in a research note, said that the Menlo Park, Calif.-based firm is "on track to be the first company to successfully commercialize third-generation sequencing technology."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.